Inventaire - your friends and communities are your best library

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.

author

Cirino Botta

Valerio Nardone

Giuseppe Battaglia

Cristiana Bellan

Marcella Barbarino

Francesca Capone

Gabriella Misso

Mariarosaria Boccellino

Michele Caraglia

2000 -

Antonio Giordano

1962 -

Piero Paladini

Maria Grazia Cusi

Pierpaolo Correale

published in: Journal of thoracic disease

date of publication: 2017-09-01

main subject: bevacizumab

Cites articles 45

Date

Title

Authors

2016-10-03

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients

Gabriella Misso, Cirino Botta, Maria Grazia Cusi, Pierpaolo Correale
2016-04-30

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016

Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition

Vasily Rybakin, Joanna Brzostek, Nicholas R J Gascoigne
2015-12-18

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

José Luis Pérez-Gracia, Enriqueta Felip, Roy S. Herbst, Julian R Molina
2015-11-03

Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer
2015-09-29

Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs

Kea Martin
2015-05-31

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Karen L. Reckamp, Marina Garassino, Everett E Vokes, Adam Pluzanski
2015-03-23

Nivolumab: targeting PD-1 to bolster antitumor immunity
2015-03-01

Nivolumab in NSCLC: latest evidence and clinical potential

Raghav Sundar, Byoung Chul Cho
2015-02-01

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma
2015-02-06

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington
2014-12-23

Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance

David J. Waxman
2014-07-01

Metronomic chemotherapy
2014-07-01

Biochemical signaling of PD-1 on T cells and its functional implications
2014-05-29

Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis

Mairéad Mcnamara, Alberto Ocana, Eitan Amir, Ian F. Tannock, Arnoud J Templeton, Boštjan Šeruga, Francisco Vera-Badillo, Priya Aneja, Raya Leibowitz-Amit
2014-04-29

The Treg/Th17 paradigm in lung cancer
2014

Control of the immune response by pro-angiogenic factors

Eric Tartour, Magali Terme, Julien Taïeb
2014-01

Update on immune checkpoint inhibitors in lung cancer
2013-06-01

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients

Cesare Gridelli, Pierosandro Tagliaferri, Pierfrancesco Tassone
2013-03-27

Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
2012-12-24

Modulation of immunity by antiangiogenic molecules in cancer

Eric Tartour, Magali Terme, Julien Taïeb, Elie Marcheteau
2012-12-27

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery
2012-09-01

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
2012-04-30

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study

Igor N. Bondarenko, Piotr Serwatowski
2012-04-30

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial

Igor N. Bondarenko, Ihor Vynnychenko
2012-03-22

The blockade of immune checkpoints in cancer immunotherapy

Drew M Pardoll
2012-01-01

CD4+, IL17 and Foxp3 expression in different pTNM stages of operable non-small cell lung cancer and effects on disease prognosis
2011-09-01

Cancer vaccines inducing antibody production: more pros than cons

Erika Jensen-Jarolim
2011-07-15

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Gabriella Misso, Michele Caraglia, Raffaele Addeo, Cirino Botta, Pierpaolo Correale
2011-01-01

Immunomodulatory properties of anticancer monoclonal antibodies: is the 'magic bullet' still a reliable paradigm?

Pierpaolo Correale, Maria Grazia Cusi
2010-05-01

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients

Pierpaolo Correale, Michele Caraglia, Salvatore Francesco Carbone
2009-12-22

CCR7 regulates lymphocyte egress and recirculation through body cavities.

Uta E Höpken, Martin Lipp

Article - wd:Q47104348

Welcome to Inventaire

the library of your friends and communities

learn more